Safety Alerts & Recalls

Search all Safety Alerts & Recalls

Latest Alerts

Eclectic Institute Recall Specific Dietary Supplements Containing Gotu Kola (Centella Asiatica) And Bladderwrack (Fucus Vesiculosus) Due to Possible Bacteria Contamination
Eclectic Institute of Sandy, Oregon is voluntarily recalling specific lots of its freeze-dried capsules containing Gotu Kola (Centella asiatica) and Bladderwrack (Fucus vesiculosus) capsules because of possible contamination with the bacteria Salmonella. Salmonella is an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems. Healthy persons infected with Salmonella often experience fever, diarrhea, nausea, vomiting and abdominal pain. In rare circumstances, Salmonella infection can result in the organism getting into the bloodstream and producing more severe infections, endocarditis and arthritis. No adverse effects or illnesses have been reported to date in connection with either of these products. This recall affects only select lot number of Centella asiatica, Gotu Kola, Ginkgo/Gotu Kola combination, Fucus vesiculosus, and Bladderwrack made by Eclectic Institute. These products were sold to retailers, individuals, and health practitioners throughout the United States. No other Eclectic Institute products are affected by this recall. All of the freeze-dried capsules were packaged in either glass or plastic bottles. Lot numbers can be found on the bottom of the label of the product. For more information and to see a list of recalled lot numbers, please visit: http://www.fda.gov/Safety/Recalls/ucm284454.htm?source=govdelivery
Learn More

McNeil Recalls Certain Lots of Motrin
McNeil Consumer Healthcare is asking retailers to remove about 12 million bottles of Motrin pain relievers from store shelves. The coated caplets may not dissolve as quickly as intended when they near their expiration dates, the company found when testing product samples. This is not a consumer level recall, which means that consumers do not need to throw away or return the product. There is no safety concern if consumers continue taking the product as directed by its label; however, it is possible there may be a delay in experiencing relief. This recall is not being undertaken on the basis of adverse events. Three different Motrin products are being recalled: MOTRIN IB 24 count COATED CAPLETS, MOTRIN IB 24 count COATED TABLETS and MOTRIN IB 24+6 count COATED CAPLETS. For more information and to view a list of recalled lot numbers, please visit: http://www.motrin.com/news/7
Learn More

Date Published Title Drug Source
2011-12-22 Eclectic Institute Recall Specific Dietary Supplements Containing Gotu Kola (Centella Asiatica) And Bladderwrack (Fucus Vesiculosus) Due to Possible Bacteria Contamination FDA
2011-12-22 McNeil Recalls Certain Lots of Motrin Ibuprofen Manufacturer
2011-12-22 Nycomed Recalls Select Lots of Omnaris (ciclesonide) Nasal Spray, 50mcg Ciclesonide Nasal FDA
2011-12-20 FDA Announces Safety Review of a Reported Death After the First Dose of Gilenya Fingolimod FDA
2011-12-19 FDA Completes Safety Review of Multaq and Updates Prescribing Information Dronedarone FDA
2011-12-15 FDA Revises Dose Limitation for Zocor (simvastatin) When Taken with Amiodarone Simvastatin FDA
2011-12-15 FDA Update: Safety Information for Antidepressant Use During Pregnancy Paroxetine FDA
2011-12-14 FDA Warns HCG Diet Products Are Illegal FDA
2011-12-14 Novartis Looking into Death of MS Patient Who Took Gilenya Fingolimod MediGuard CRT
2011-12-08 FDA Evaluating Reports of Bleeding in Patients Taking Pradaxa Dabigatran FDA
2011-12-06 Corepharma LLC Recalls Several Lots of Ropinirole Hydrochloride Tablets, 0.25, 0.5, 1, 2 mg Ropinirole FDA
2011-12-06 G & W Laboratories Inc. Recalls Single Lot of Migergot (Ergotamine Tartrate and Caffeine Suppositories) Caffeine with Ergotamine Tartrate FDA
2011-11-21 FDA Announces Avastin Not Shown to Be Safe and Effective in Breast Cancer Patients Bevacizumab FDA
2011-11-17 FDA Requests a Stop to the Distribution of Pennsaid Samples Diclofenac FDA
2011-11-09 FDA: Trilipix (fenofibric acid) May Not Lower a Patient's Risk of Having a Heart Attack or Stroke Fenofibric Acid FDA
2011-11-09 Manufacturing Delays May Affect Availability of Antibiotic Tetracycline Tetracycline FDA
2011-11-09 FDA Issues Safety Review Update of Medications Used to Treat Attention-Deficit/Hyperactivity Disorder (ADHD) Atomoxetine FDA
2011-11-04 FDA Reminds Healthcare Providers and Patients to Enroll in the Avandia-Rosiglitazone Medicines Access Program Glimepiride and Rosiglitazone FDA
2011-11-04 FDA Requires Closer Review of Adverse Event Reports for Tumor Necrosis Factor (TNF) Blockers Etanercept FDA
2011-11-02 FDA Issues Safety Review Update of Medications Used to Treat Attention-Deficit/Hyperactivity Disorder (ADHD) Lisdexamfetamine FDA
Back to Consumer Med Safety